Jiangsu Bioperfectus Financials
| 688399 Stock | 70.20 0.17 0.24% |
Operating Margin 0.3169 | Profit Margin (0.43) | Return On Equity (0.05) |
Jiangsu | Select Account or Indicator |
Understanding current and past Jiangsu Bioperfectus Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Jiangsu Bioperfectus' financial statements are interrelated, with each one affecting the others. For example, an increase in Jiangsu Bioperfectus' assets may result in an increase in income on the income statement.
Please note, the presentation of Jiangsu Bioperfectus' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Jiangsu Bioperfectus' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Jiangsu Bioperfectus' management manipulating its earnings.
Jiangsu Bioperfectus Stock Summary
Jiangsu Bioperfectus competes with China Railway, Zhongshan Public, Guangdong Wens, Shanghai Ziyan, and Keda Clean. Jiangsu Bioperfectus is entity of China. It is traded as Stock on SHG exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | China Stock View All |
| Exchange | Shanghai Stock Exchange |
| ISIN | CNE1000055B2 |
| Business Address | Bioperfectus Technologies Industrial |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.s-sbio.com |
| Phone | 86 52 3802 25599 |
You should never invest in Jiangsu Bioperfectus without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Jiangsu Stock, because this is throwing your money away. Analyzing the key information contained in Jiangsu Bioperfectus' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Jiangsu Bioperfectus Key Financial Ratios
Jiangsu Bioperfectus' financial ratios allow both analysts and investors to convert raw data from Jiangsu Bioperfectus' financial statements into concise, actionable information that can be used to evaluate the performance of Jiangsu Bioperfectus over time and compare it to other companies across industries.| Revenue | 403.18 M | ||||
| Gross Profit | 3.35 B | ||||
| EBITDA | (149.31 M) | ||||
| Net Income | (384.39 M) | ||||
| Total Asset | 3.91 B |
Jiangsu Bioperfectus Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 1.2B | 2.3B | 3.5B | 4.9B | 3.9B | 2.3B | |
| Retained Earnings | 157.5M | 801.2M | 1.7B | 2.9B | 2.5B | 2.6B | |
| Accounts Payable | 9.2M | 79.2M | 132.5M | 433.1M | 75.0M | 103.1M | |
| Cash | 248.7M | 1.1B | 1.3B | 1.8B | 1.8B | 891.4M | |
| Net Receivables | 39.7M | 157.5M | 342.6M | 564.0M | 108.7M | 173.3M | |
| Inventory | 19.0M | 162.9M | 250.3M | 236.3M | 93.9M | 111.3M | |
| Other Current Assets | 2.4M | 14.3M | 24.2M | 49.3M | 18.8M | 31.0M | |
| Total Liab | 133.6M | 613.2M | 962.9M | 1.1B | 501.3M | 478.5M | |
| Total Current Assets | 890.5M | 1.8B | 2.5B | 3.7B | 2.7B | 1.7B | |
| Intangible Assets | 25.6M | 26.6M | 26.8M | 27.4M | 29.9M | 23.0M | |
| Other Current Liab | 64.3M | 197.3M | 368.1M | 242.1M | 408.9K | 388.5K | |
| Other Liab | 39.3M | 90.7M | 100.4M | 169.7M | 195.2M | 205.0M | |
| Net Tangible Assets | 995.2M | 1.6B | 2.5B | 3.8B | 4.3B | 4.5B | |
| Other Assets | 18.4M | 52.4M | 95.8M | 168.6M | 193.9M | 203.6M | |
| Net Invested Capital | 1.0B | 1.7B | 2.7B | 3.9B | 3.6B | 2.1B | |
| Net Working Capital | 796.2M | 1.3B | 1.7B | 2.8B | 2.3B | 1.5B |
Jiangsu Bioperfectus Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Tax Provision | 10.9M | 141.4M | 198.6M | 310.8M | (1.9M) | (1.8M) | |
| Net Interest Income | 3.9M | 7.5M | 22.6M | 33.4M | 48.9M | 51.3M | |
| Interest Expense | 3.9M | 83.1K | 4.0M | 5.3M | 6.9M | 7.3M | |
| Total Revenue | 288.8M | 1.7B | 2.8B | 5.5B | 403.2M | 383.0M | |
| Gross Profit | 236.1M | 1.3B | 2.0B | 3.4B | 257.7M | 244.8M | |
| Operating Income | 91.0M | 939.1M | 1.4B | 2.5B | (214.5M) | (203.8M) | |
| Ebit | 83.4M | 911.0M | 1.3B | 2.5B | 2.8B | 3.0B | |
| Research Development | 38.6M | 72.1M | 106.6M | 185.8M | 135.5M | 82.6M | |
| Cost Of Revenue | 52.7M | 389.9M | 876.3M | 2.2B | 145.5M | 138.2M | |
| Income Before Tax | 94.7M | 961.0M | 1.4B | 2.1B | (375.7M) | (356.9M) | |
| Net Income | 83.8M | 819.6M | 1.2B | 1.8B | (373.8M) | (355.1M) | |
| Interest Income | 4.0M | 7.8M | 26.8M | 39.2M | 56.0M | 58.8M | |
| Ebitda | 108.1M | 983.2M | 1.4B | 2.2B | 2.6B | 2.7B | |
| Income Tax Expense | 10.9M | 141.4M | 198.6M | 310.8M | 357.4M | 375.3M |
Jiangsu Bioperfectus Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Jiangsu Bioperfectus. It measures of how well Jiangsu is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Jiangsu Bioperfectus brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Jiangsu had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Jiangsu Bioperfectus has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (5.0M) | (144.7M) | (91.1M) | (186.3M) | 34.0M | 35.7M | |
| Investments | (550M) | (133.5M) | (450.4M) | (470.2M) | 462.3M | 485.5M | |
| Change In Cash | 65.2M | 548.8M | 1.4M | 580.3M | 403.2M | 212.9M | |
| Depreciation | 17.4M | 22.1M | 40.8M | 94.0M | 78.9M | 82.9M | |
| Capital Expenditures | 105.8M | 134.6M | 303.6M | 350.7M | 111.3M | 159.1M | |
| Net Income | 83.8M | 819.6M | 1.2B | 1.8B | (384.4M) | (365.2M) | |
| End Period Cash Flow | 97.4M | 646.1M | 647.5M | 1.2B | 1.6B | 1.7B | |
| Free Cash Flow | 944.3K | 801.3M | 681.9M | 1.6B | (224.5M) | (213.3M) | |
| Other Non Cash Items | 3.3M | 4.8M | 16.1M | 21.6M | 40.0M | 42.0M | |
| Change To Netincome | 448.5K | (16.1M) | (10.6M) | 353.7M | 406.8M | 427.1M |
Jiangsu Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Jiangsu Bioperfectus's current stock value. Our valuation model uses many indicators to compare Jiangsu Bioperfectus value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Jiangsu Bioperfectus competition to find correlations between indicators driving Jiangsu Bioperfectus's intrinsic value. More Info.Jiangsu Bioperfectus Technologies is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Jiangsu Bioperfectus by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Jiangsu Bioperfectus' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Jiangsu Bioperfectus Systematic Risk
Jiangsu Bioperfectus' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Jiangsu Bioperfectus volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Jiangsu Bioperfectus correlated with the market. If Beta is less than 0 Jiangsu Bioperfectus generally moves in the opposite direction as compared to the market. If Jiangsu Bioperfectus Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Jiangsu Bioperfectus is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Jiangsu Bioperfectus is generally in the same direction as the market. If Beta > 1 Jiangsu Bioperfectus moves generally in the same direction as, but more than the movement of the benchmark.
Jiangsu Bioperfectus Technologies Total Assets Over Time
Jiangsu Bioperfectus December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Jiangsu Bioperfectus help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Jiangsu Bioperfectus Technologies. We use our internally-developed statistical techniques to arrive at the intrinsic value of Jiangsu Bioperfectus Technologies based on widely used predictive technical indicators. In general, we focus on analyzing Jiangsu Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Jiangsu Bioperfectus's daily price indicators and compare them against related drivers.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 20.86 | |||
| Value At Risk | (4.33) | |||
| Potential Upside | 4.07 |
Complementary Tools for Jiangsu Stock analysis
When running Jiangsu Bioperfectus' price analysis, check to measure Jiangsu Bioperfectus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jiangsu Bioperfectus is operating at the current time. Most of Jiangsu Bioperfectus' value examination focuses on studying past and present price action to predict the probability of Jiangsu Bioperfectus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jiangsu Bioperfectus' price. Additionally, you may evaluate how the addition of Jiangsu Bioperfectus to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |